Tenax Therapeutics Inc (TENX)

[Rumpelstilz]

Scottish State institutions being informed on Tenax’s SEC problem

Rumpelstilz announces that he has started to bring this Investorshub discussion board to the attention of Scottish Stakeholders and State institutions. For the time being, only such stakeholders and institutions have been informed that are in favor of the use of public Scottish money for the development of Tenax’s privately-owned drug Oxycyte as part of a new MRI technology. These Scottish Stakeholders and institutions can now analyze, verify and judge the relevance of the information given in my postings. They then shall draw their own conclusions and take such actions as they deem necessary and adequate to defend Scottish investments into ICE and the Tenax-Aurum deal for the development of Oxycyte.

Four revealing sources

All information given in my postings is based on publicly accessible official documents and company homepages. The most striking insights comes from the following four sources:

1-SEC Filing “FORM 10-K, ANNUAL REPORT, for the fiscal year ended December 31, 2016, Commission File No. 001-34600”.
In this filing Tenax tells the United States Securities and Exchange Commission (SEC) that all development of Oxycyte has been suspended and that Oxycyte is of no importance for Tenax’s future business. Scroll down about 6 pages to the title “Other Products”. There you will find the following statement: “As we have suspended the development of these PFC products while we evaluate strategic alternatives, we do not expect that Oxycyte, Dermacyte or Wundecyte constitute a material portion of our business going forward.” (http://secfilings.nasdaq.com/edgar_conv_html%2f2017%2f03%2f16%2f0001654954-17-002098.html#FIS_BUSINESS)

2-Homepage of Aurum Biosciences, Investor Information.
In contrast to Tenax’s SEC filings stands the information given by Tenax's development partner Aurum Biosciences, the Scottish brain imaging company. They inform their investors: “Aurum also signed a major research, development and commercialisation deal with its US partner, Tenax Therapeutics, to develop Oxycyte, initially in the lead stroke indication. … Under the terms of this deal, the companies will share the benefits in stroke.” This statement clearly shows that (a) development of Oxycyte is not suspended but ongoing, and (b) that Oxycyte is not irrelevant to Tenax’s future business because the future benefits will be shared. (www.aurumbiosciences.com > Investor Information)

3-Homepage of Aurum Biosciences, News.
Aurum informs that a phase 2a trial with Oxycyte will be initiated soon. The announcement reads as follows: “Aurum Biosciences Ltd … has received approval from the UK regulatory authority (MHRA) for a Phase 2 clinical trial due to start in Q1 2018. … Aurum’s ABL-101 stroke technology is based on an oxygen carrying perflurocarbon (PFC) [i.e. Oxycyte], which is emulsified for intravenous use.” (www.aurumbiosciences.com > News > Aurum Biosciences receives UK regulatory approval for a Phase 2 trial)

4- Information deleted from Tenax’s homepage.
In contrast to the Information given by Aurum about Oxycyte, no information at all can be found on Tenax’s homepage: Aurum and Oxycyte, these two words don't show up at all. Tenax not only seems to be denying the existence of Oxycyte but also the longstanding development partnership with Aurum. This “strategy of denying” is very active, because shortly after the announcement of the upcoming phase 2a trial by Aurum, Tenax deleted all remaining information on Oxycte and the Tenax-Aurum partnership (about 3 weeks ago). To make the deleted information reappear, use the following Webarchive link: https://web.archive.org/web/20170723172111/http://www.tenaxthera.com/pipeline/oxycyte/

Scottish State investment is in danger

At the moment, Tenax Therapeutics is at the brink of delisting from NASDAQ. The fact that Tenax's management are trying to hide Oxycyte and Aurum from the SEC as well as from their investors shows that a powerful hidden agenda is operating. Tenax could implode at any moment into a heap of smoldering nothing. The Tenax boys then would run away in all directions, and the supply of Oxycyte to Aurum and the ICE would stop and could not be enforced, very simply because there would be nobody left to talk to. Therefore, the necessary enforcing measures should be taken now: the SEC should be invited to review Tenax’s SEC filings at once.

In case the initially mentioned Scottish stakeholders and institutions do not take due measures in due time, Rumpelstilz will bring the existence of this Investorshub discussion board to the attention of those Scottish politicians, decision makers and public media opposed to excessive state-funding of ICE, QEUH and Aurum Biosciences – especially, if this public money serves to promote a privately and foreign-owned drug like Oxycyte. These groups will no doubt be swift in using the information Rumpelstilz has deposited in this discussion board.